Objectives: To evaluate the usage of different guidelines and to estimate the impact of changed recommendation in routine management, therapy and follow-up of patients with renal cell cancer (RCC). Methods: An anonymous questionnaire was sent to 600 urologists in Germany. Twenty-seven percent of them were included in the analysis. The questions were about the practice setting, surgical and medical treatment of RCC, follow-up modalities, knowledge and usage of RCC guidelines. Results were correlated with the recommendations of the EAU-guideline. Results: Sixty-eight percent of the urologists were office based. Sixty percent were located in bigger cities. Ninety-eight percent of the colleagues reported to be knowledgeable about the EAU-guidelines, 62% reported to know the American Urological Association, 59% DGU/AWMF, 19% National Comprehensive Cancer Network, 19% European Society for Medical Oncology, 13% Onkopedia, and 3% British Association of Urological Surgeons-guidelines. Eighty-seven percent reported that partial nephrectomy (Nx) was performed in tumours with diameter <4 cm. Forty-one percent performed a radical Nx for tumours that were 4-7 cm. Follow-up of RCC was done in 99%. Fifty-nine percent underwent an abdominal CT scan after 6 months. Thirty-nine percent got a chest X-ray done. Among those with metastatic RCC, only 84% were offered systemic therapy. First-line therapy was predominantly advocated using sunitinib. Conclusion: Almost all urologists know and use the EAU-guidelines. Other guidelines are rarely used. Follow-up is performed in discordance with the EAU-recommendations. Interestingly, only 84% with metastatic disease are introduced to systemic therapy.

Keywords:
Metastatic renal cell cancer, Renal cell cancer, Guidelines, Follow-up, Surgical management
1.
Robert Koch Institut. http://www.rki.de (cited December 29, 2015).
2.
Scosyrev E, Messing EM, Sylvester R, Campbell S, Van Poppel H: Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur Urol 2014;65:372-377.
3.
Bruno JJ 2nd, Snyder ME, Motzer RJ, Russo P: Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival. BJU Int 2006;97:933-938.
4.
Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ, et al: Renal cell carcinoma guideline. Eur Urol 2007;51:1502-1510.
5.
Lipworth L, Tarone RE, McLaughlin JK: The epidemiology of renal cell carcinoma. J Urol 2006;176(6 pt 1):2353-2358.
6.
Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al: EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015;67:913-924.
7.
Andrew C. Novick M, Chair; Steven C. Campbell, MD, PhD, Co-Chair; Arie Belldegrun, MD; Michael L. Blute, MD; George Kuoche Chow, MD; Ithaar H. Derweesh, MD; Jihad H. Kaouk, MD; Raymond J. Leveillee, MD, FRCS-G; Surena F. Matin, MD; Paul Russo, MD; Robert Guy Uzzo, MD: Guideline for Management of the Clinical Stage 1 Renal Mass: American Urological Association Education and Research, 2009. https://www.auanet.org/education/guidelines/renal-mass.cfm (cited December 29, 2015).
8.
Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, et al: Kidney cancer, version 3.2015. J Natl Compr Canc Netw 2015;13:151-159.
9.
Escudier B, Eisen T, Porta C, Patard JJ, Khoo V, Algaba F, et al: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(suppl 7):vii65-vii71.
10.
Kirchner H, Casper J, Gauler T, Overkamp F, Schmidinger M, Staehler M, Stenner-Liewen F, Wörmann BJ, Santis M: Onkopedia Leitlinie Nierenzellkarzinom (Hypernephrom) Onkopedia. 2013. https://www.onkopedia.com/de/onkopedia/guidelines/nierenzellkarzinom-hypernephrom/@@view/html/index.html (updated February 1, 2013).
11.
BUG: MDT (Multi-Disciplinary Team) guidance for managing kidney cancer. http://www.baus.org.uk/professionals/baus_business/publications/22/renal_cancer_mdt2013 (published May 2012; posted September 2013).
12.
Schlenker B, Seitz M, Bader MJ, Ganzer R, Tilki D, Bayrle F, et al: Comparison of guideline recommendations with daily practice in patients with renal cell carcinoma. Eur J Med Res 2010;15:253-257.
13.
Margulis V, Tamboli P, Jacobsohn KM, Swanson DA, Wood CG: Oncological efficacy and safety of nephron-sparing surgery for selected patients with locally advanced renal cell carcinoma. BJU Int 2007;100:1235-1239.
14.
Zini L, Perrotte P, Capitanio U, Jeldres C, Shariat SF, Antebi E, et al: Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer 2009;115:1465-1471.
15.
Patard JJ, Shvarts O, Lam JS, Pantuck AJ, Kim HL, Ficarra V, et al: Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 2004;171(6 pt 1):2181-2185, quiz 2435.
16.
Meyer C, Hansen J, Becker A, Schmid M, Pradel L, Strini K, et al: The adoption of nephron-sparing surgery in Europe - a trend analysis in two referral centers from Austria and Germany. Urol Int 2016;96:330-336.
17.
Bani-Hani AH, Leibovich BC, Lohse CM, Cheville JC, Zincke H, Blute ML: Associations with contralateral recurrence following nephrectomy for renal cell carcinoma using a cohort of 2,352 patients. J Urol 2005;173:391-394.
18.
Levy DA, Slaton JW, Swanson DA, Dinney CP: Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998;159:1163-1167.
19.
Hafez KS, Novick AC, Campbell SC: Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma. J Urol 1997;157:2067-2070.
20.
Johnsen JA, Hellsten S: Lymphatogenous spread of renal cell carcinoma: an autopsy study. J Urol 1997;157:450-453.
21.
Williamson TJ, Pearson JR, Ischia J, Bolton DM, Lawrentschuk N: Guideline of guidelines: follow-up after nephrectomy for renal cell carcinoma. BJU Int 2016;117:555-562.
22.
Sandhu SS, Symes A, A'Hern R, Sohaib SA, Eisen T, Gore M, et al: Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma. BJU Int 2005;95:522-525.
23.
Isbarn H, Karakiewicz PI: Predicting cancer-control outcomes in patients with renal cell carcinoma. Curr Opin Urol 2009;19:247-257.
24.
Karakiewicz PI, Suardi N, Capitanio U, Jeldres C, Ficarra V, Cindolo L, et al: A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol 2009;55:287-295.
25.
Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P: A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001;166:63-67.
26.
Russo P, Jang TL, Pettus JA, Huang WC, Eggener SE, O'Brien MF, et al: Survival rates after resection for localized kidney cancer: 1989 to 2004. Cancer 2008;113:84-96.
27.
Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, et al: Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97:1663-1671.
28.
Doornweerd BH, de Jong IJ, Bergman LM, Ananias HJ: Chest X-ray in the follow-up of renal cell carcinoma. World J Urol 2014;32:1015-1019.
29.
Coquia SF, Johnson PT, Ahmed S, Fishman EK: MDCT imaging following nephrectomy for renal cell carcinoma: protocol optimization and patterns of tumor recurrence. World J Radiol 2013;5:436-445.
30.
Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TB, Canfield SE, et al: Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol 2014;15:e549-e561.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.